CytRx was recently featured in a third article by Seeking Alpha contributor John Mylant, who writes of the potential of the company's flagship leading drug candidate, aldoxorubicin, as an alternative to widely used chemotherapeutic agent doxorubicin.
CytRx Wednesday released positive phase 2b sarcoma data, triggering a 75 percent rally in company shares. The trial results reveal the company was successful in meeting its primary endpoint of progression-free survival (NYSE:PFS), outshining PFS rates achieved with doxorubicin.
To read the full article visit seekingalpha.com/article/1895201
The overall response rate was 25.4% for aldoxorubicin subjects versus 5.4% for doxorubicin subjects. As assessed by blinded central lab review, 23.0% of aldoxorubicin subjects had a partial response while 0.0% of doxorubicin subjects exhibited any objective response.
As determined by both the trial investigators and by blinded central radiology review, subjects treated with aldoxorubicin demonstrated highly statistically significant better clinical outcomes than those receiving standard doxorubicin therapy for their soft tissue sarcomas.
Mylant has covered CytRx' progress in two other articles and says he continues to educate the investment community about the company as a long-term investment. His bullish take is supported by the recently completed clinical study, he says.
"The results continue to support my belief that CytRx Corp. is a good long-term value investment and aldoxorubicin will be the company's first huge revenue generating drug. This is amazing news for long-term investors," concludes Mylant.
For more information, visit cytrx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com